Shots: RetinAI signs a multi-year collaboration with Novartis under which RetinAI’s IT solutions and AI tools will be employed to support multiple projects in ophthalmology and digital health The first project under the agreement will support a multi-center international clinical study involving patients with nAMD. The study is designed to investigate the influence of OCT […]Read More
Shots: Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones, BioMarin will receive an exclusive option to obtain Deep Genomics’ rights to each program for development & commercialization Deep Genomics will use its AI drug discovery platform (The AI workbench) to identify & validate target mechanisms, lead candidates & […]Read More
Medical Affairs is a critical scientific bridge between Healthcare companies and their internal & external stakeholders. It plays a leadership role in implementing cutting-edge medical, scientific, and patient-centered insights & solutions that drive strategy and innovation in healthcare. The healthcare ecosystem is dynamic and being transformed with the latest tech solutions. It is believed that […]Read More
COVID-19 has casted the healthcare community into disarray. Healthcare providers are stressed as the disease has affected more people than the production capacity of healthcare companies to manufacture ventilators, personal protective equipment (PPE) and diagnostic kits. Since Business disruptions have happened, business continuity strategies are in operation. The medical technology (Medtech) industry is moving swiftly […]Read More
Shots: Novartis enters into a 3yrs. collaboration with MILA for transforming the discovery, development & commercialization of therapies by leveraging AI. The collaboration will lead to expansion of the pharmaceutical industry and AI ecosystem in Quebec, Canada The collaboration allows Novartis to actively participate in the unique and dynamic ecosystem of companies, researchers and entrepreneurs […]Read More
Shots: Janssen enters into an agreement to utilize Iktos’ AI (in silico drug design) technology for the enhancement of speed & efficacy of its small molecules discovery platform and will develop new therapies utilizing Iktos’ know-how in deep generative models applied to chemistry with its own AI expertise Additionally, Iktos has also collaborated with other […]Read More
Shots: Merck KGaA enters into an agreement with Iktos to develop therapies using Iktos’ AI technology for three drug discovery projects The focus of the agreement is to develop and advance its drug discovery techniques with the usage of Iktos’ technology enabled with AI solutions in multiple therapy areas Iktos’ AI technology is based on […]Read More
Shots: FDA grants BT designation to Paige.AI to develop AI in computational pathology for the diagnosis and treatment of cancer including prostate cancer The FDA’s BT designation is granted for technologies that provide effective diagnosis and treatment for life-threatening diseases Paige.AI is based on Fuch’s technology, works with the de-identified dataset to develop AI portfolio […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
